Passa al contenuto
Merck
Tutte le immagini(2)

Documenti

850104P

Avanti

18:0 Lyso PI

1-stearoyl-2-hydroxy-sn-glycero-3-phosphoinositol (ammonium salt), powder

Sinonimo/i:

1-octadecanoyl-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt); PI(18:0/0:0); 110719

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C27H56NO12P
Numero CAS:
849412-49-3
Peso molecolare:
617.71
Codice UNSPSC:
51191904
NACRES:
NA.25

Saggio

>99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)

Forma fisica

powder

Confezionamento

pkg of 1 × 100 μg (with stopper and crimp cap (850104P-100ug))
pkg of 1 × 500 μg (with stopper and crimp cap (850104P-500ug))

Produttore/marchio commerciale

Avanti Research™ - A Croda Brand 850104P

Tipo di lipide

phosphoglycerides

Condizioni di spedizione

dry ice

Temperatura di conservazione

−20°C

Stringa SMILE

[H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCCCCCCCCCCC)=O.[NH4+]

Descrizione generale

Lysophosphatidylinositol (LPI), an acidic lysophosholipid, carries inositol in its head group.

Applicazioni

18:0 Lyso PI (1-stearoyl-2-hydroxy-sn-glycero-3-phosphoinositol) has been used as lysophosphatidylinositol (LPI) substrate in lysophosphatidylinositol acyltransferase biochemical assay to determine lyso-phosphatidylinositol acyltransferase (LPIAT) activity of liver microsomes. It may be used as a synthetic LPI to compare its effects with liver LPI in transferrin (Tf) endocytosis. It may also be used as LPI standard to quantify serum LPI levels in gonadectomized rats.

Azioni biochim/fisiol

Increased circulating levels of L-alpha-lysophosphatidylinositol (LPI) are associated with cancer and LPI is a potent ligand for the G-protein-coupled receptor GPR55.
Lysophosphatidylinositol (LPI) displays mitogenic activity and can serve as a bioactive lysophospholipid mediator. It may be considered as a lipid mediator.

Confezionamento

2 mL Amber Serum Vial with Stopper and Crimp Cap (850104P-100ug)
2 mL Amber Serum Vial with Stopper and Crimp Cap (850104P-500ug)

Note legali

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Comunemente ordinati con questo prodotto

N° Catalogo
Descrizione
Determinazione del prezzo

Codice della classe di stoccaggio

11 - Combustible Solids

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 1

1 of 1

17:1 Lyso PI 1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phospho-(1′-myo-inositol) (ammonium salt), powder

Avanti

850103P

17:1 Lyso PI

Monica Imbernon et al.
Molecular and cellular endocrinology, 383(1-2), 159-169 (2014-01-01)
The G protein-coupled receptor GPR55 has been proposed as a new cannabinoid receptor associated with obesity in humans. We have investigated the regulation of GPR55 in rat white adipose tissue (WAT) in different physiological and pathophysiological settings involved in energy
Saori Oka et al.
Biochemical and biophysical research communications, 362(4), 928-934 (2007-09-04)
GPR55 is an orphan G protein-coupled receptor. In this study, we explored a possible endogenous ligand for GPR55 using HEK293 cells which expressed GPR55. We found that lysophosphatidylinositol induced rapid phosphorylation of the extracellular signal-regulated kinase in transiently or stably
Robert N Helsley et al.
eLife, 8 (2019-10-18)
Recent studies have identified a genetic variant rs641738 near two genes encoding membrane bound O-acyltransferase domain-containing 7 (MBOAT7) and transmembrane channel-like 4 (TMC4) that associate with increased risk of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcohol-related cirrhosis, and
Atsushi Yamashita et al.
Prostaglandins & other lipid mediators, 107, 103-116 (2013-05-30)
Lysophosphatidylinositol (LPI) is a subspecies of lysophospholipid and is assumed to be not only a degradation product of phosphatidylinositol (PI), but also a bioactive lysophospholipid mediator. However, not much attention has been directed toward LPI compared to lysophosphatidic acid (LPA)
Ieva Ailte et al.
Traffic (Copenhagen, Denmark), 18(3), 176-191 (2017-01-10)
In this study, we have investigated how clathrin-dependent endocytosis is affected by exogenously added lysophospholipids (LPLs). Addition of LPLs with large head groups strongly inhibits transferrin (Tf) endocytosis in various cell lines, while LPLs with small head groups do not.
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.